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Abstract
Background: Decreased bone mineral density and osteoporosis in postmenopausal women represents a growing
source of physical limitations and financial concerns in our aging population. While appropriate medical treatments
such as bisphosphonate drugs and hormone replacement therapy exist, they are associated with serious side
effects such as osteonecrosis of the jaw or increased cardiovascular risk. In addition to calcium and vitamin D
supplementation, previous studies have demonstrated a beneficial effect of dietary silicon on bone health. This
study evaluated the absorption of silicon from bottled artesian aquifer water and its effect on markers of bone
metabolism.
Methods: Seventeen postmenopausal women with low bone mass, but without osteopenia or osteoporosis as
determined by dual x-ray absorptiometry (DEXA) were randomized to drink one liter daily of either purified water
of low-silicon content (PW) or silicon-rich artesian aquifer water (SW) (86 mg/L silica) for 12 weeks. Urinary silicon
and serum markers of bone metabolism were measured at baseline and after 12 weeks and analyzed with two-
sided t-tests with p < 0.05 defined as significant.
Results: The urinary silicon level increased significantly from 0.016 ± 0.010 mg/mg creatinine at baseline to 0.037 ±
0.014 mg/mg creatinine at week 12 in the SW group (p = 0.003), but there was no change for the PW group
(0.010 ± 0.004 mg/mg creatinine at baseline vs. 0.009 ± 0.006 mg/mg creatinine at week 12, p = 0.679). The urinary
silicon for the SW group was significantly higher in the silicon-rich water group compared to the purified water
group (p < 0.01). NTx, a urinary marker of bone resorption did not change during the study and was not affected
by the silicon water supplementation. No significant change was observed in the serum markers of bone formation
compared to baseline measurements for either group.
Conclusions: These findings indicate that bottled water from artesian aquifers is a safe and effective way of
providing easily absorbed dietary silicon to the body. Although the silicon did not affect bone turnover markers in
the short-term, the mineral’s potential as an alternative prevention or treatment to drug therapy for osteoporosis
warrants further longer-term investigation in the future.
Trial Registration: ClinicalTrials.gov Identifier: NCT01067508.
Background
Osteoporosis is a leading cause of morbidity and mortal-
ity in the elderly [1]. In the U.S., an estimated 4-6 mil-
lion women aged >50 years have osteoporosis, and
another 13-17 million (37%-50%) have osteopenia (or
low bone density) based on femoral bone mineral
density (BMD) tests using dual x-ray absorptiometry
(DEXA) when osteoporosis is defined by a T-score of
less than -2 while osteopenia is defined as having a
T-score between -2 and -1.5 [1]. As a result of demo-
graphic shifts and an aging population in the U.S. there
has been a significant increase in the number of adults
with low femoral neck BMD (osteoporosis + osteopenia)
in 2005-2006 compared to the number identified
between 1988 and1994 [2]. Osteoporosis causes 1.5
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any medium, provided the original work is properly cited.million fractures in the U.S. annually, including 300,000
hip fractures and 700,000 vertebral spine fractures [3].
The estimated cost of treating osteoporotic fractures in
2005 was $17 billion, and this cost is expected to
increase by 50% by 2025 as the population ages [4].
Beyond genetic and hormonal factors that affect bone
density with aging, lifestyle factors including inadequate
intake of calcium and vitamin D, smoking, excessive
alcohol use, regular consumption of soft drinks, lack of
physical exercise, and lack of fruit and vegetable intake
exacerbate decreases in bone density which increase the
risk for bone fracture [5-8]. Clinicians commonly
recommend calcium and vitamin D supplementation,
bisphosphonate drugs, strontium ranelate, calcitonin,
parathyroid hormone, estrogen, and some anti-estrogens
with weak estrogen effects to women with reduced bone
density in order to reduce bone turnover, but have paid
less attention to nutritional factors such as reducing soft
drink consumption [9]. While appropriate for treating
osteoporosis, these medical approaches have been asso-
ciated with serious side effects such as osteonecrosis of
the jaw in patients receiving oral bisphosphonates [10],
and increased risks of breast cancer, stroke, and venous
thromboembolism in women treated with postmenopau-
sal hormone replacement therapy [11].
Silicon (Si) is the most abundant trace element in the
diet after iron and zinc. In 1970, Carlisle suggested that
silicon is a possible factor in bone calcification [12]. The
dietary consumption of silicon and other trace minerals
has been associated positively with bone mass, while
mineral deficiencies have been associated with reduced
bone density [13,14]. Animal studies in the 1970’s
reported that dietary silicon deficiency resulted in
reduced bone tensile strength [15,16]. In the Framing-
ham offspring cohort, increased dietary silicon intake
was associated with increased bone mass [17].
Drinking water and other flui d sp r o v i d eas i g n i f i c a n t
potential dietary source of silicon, since silicon is pri-
marily present in water as Si(OH)4 [18]. Bottled water
from artesian aquifers contains silicon obtained from
volcanic rock while typical bottled water, an increasingly
popular alternative to soft drinks, is purified through
reverse osmosis and does not contain significant
amounts of any trace minerals. In comparison with the
silicon-rich water which contains 85 to 90 mg/L silica,
the purified water contains undetectable amount of
silica. Beer contains 0.9 to 3.94 mg silicon/100 gram and
is another potentially beneficial source of silicon for
healthy bone [19]. However, heavy beer drinking is asso-
ciated with a reduced trabecular bone density in the
spine [20]. Water originating from artesian aquifers
represents a good source of dietary silicon, without the
disadvantages arising from increased consumption of
beer. The present study was carried out in
postmenopausal women with reduced bone density con-
firmed by DEXA in order to determine the absorption
of silicon from artesian drinking water and its effects on
bone remodeling markers as assessed by accepted meta-




Postmenopausal women within 5 years of menopause
were recruited into the study. They were required to
have reduced bone density but no evidence of osteo-
porosis or osteopenia by DEXA scan (T ≥ -1.5 in the
total hip and lumbar spine). Women with a body mass
index (BMI) >30 kg/m
2 or who were being treated with
estrogens, corticosteroids, or bisphosphonates, who con-
sumed more than one alcoholic beverage a day, or who
had significant illness affecting bone metabolism were
excluded.
The study protocol was approved by the Institutional
Review Board at the University of California, Los
Angeles (UCLA) and was conducted at the UCLA Cen-
ter for Human Nutrition. All subjects gave written
informed consent prior to participation in the study. All
study methods and procedures were conducted in accor-
dance with the ethical standards of the Declaration of
Helsinki and Good Clinical Practice Guidelines.
Study Design
This was a 12 week, randomized, placebo-controlled,
interventional study. Subjects who met the inclusion
and exclusion criteria were instructed to take 1200 mg
of calcium and 800 IU of vitamin D (Caltrate 600+D
Calcium Supplement, Wyeth Consumer Healthcare,
Madison, NJ, USA) daily during a two week run-in and
to continue this supplementation throughout the study.
At baseline, subjects were randomized either to the sili-
con-rich water group (SW) or the purified water group
of low-silicon content (PW). The SW group received
bottled FIJI Water® (FIJI Water LLC, Los Angeles, CA,
USA) and the PW group received purified bottled water
(Aguafina® water, Pepsico, Inc.). Subjects were instructed
to drink one liter of study provided water daily directly
from the bottle. New batch of water was dispensed and
empty water bottles were collected every 4 weeks to
ensure compliance with the protocol. Subjects were
instructed not to alter their activity level or diets in any
way outside of consuming the water and supplements
provided to them by the study.
Measurements
A basic clinical examination including measurement of
body weight, systolic and diastolic blood pressure and
heart rate was performed at screening, baseline visit and
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10 hours prior to their clinic visits. Fasting blood sam-
ples (18 ml per time point) and fasting single void, mid-
stream spot urine samples were collected at screening,
baseline and week 12 during morning appointments.
The blood samples were measured for 25-hydroxy vita-
min D, parathyroid hormone (PTH), procollagen type I
intact N-terminal propeptide, bone specific alkaline
phosphatase and osteocalcin; urine samples were ana-
lyzed for silicon, creatinine, calcium and collagen type 1
cross-linked N-telopeptide (NTx).
Urine silicon concentration was measured by NMS
Labs (Willow Grove, PA, USA) using inductively
coupled plasma atomic emission spectroscopy (ICP-
AES). The calibration range is from 1 to 10 mcg/L with
two urine controls at 4 and 10 mg/L. These were pre-
pared using a 10 mg/mL solution of silicone in water
with 0.4% F-. The %CV for the low control was 6.4 and
for the high control was 5.2. All the other blood and
urine samples were analyzed by the Ronald Reagan
UCLA Medical Center Clinical Laboratory (CLIA and
CAP certified) using commercially available kits.
Statistical analysis
Results are expressed as means ± standard deviation
(SD). Differences between the two groups were evalu-
ated with t-tests. All tests are two-sided and p < 0.05
was defined as significant.
Results
Bottled waters
The silica content in the bottled water was measured at
MWH Laboratories (Monrovia, California, USA) by the
method of EPA 200.7-ICP and the test results met all
NELAC (National Environmental Laboratory Accredita-
tion Conference) requirements. The silicon-rich water
contained 86 mg/L of silica while the purified bottled
water contained no detectable amount.
Subjects
41 post-menopausal women with reduced bone density
were screened for the study. Twenty-two subjects did
not meet the inclusion criteria and were excluded from
participation. Two subjects withdrew from the study
after the baseline visit, one due to time constraints and
the other at the request of the investigator concerning
for her cardiovascular health. The remaining 17 women
completed the study. Both PW and SW were well toler-
ated without adverse events.
The average age was 54 years, BMI of 24.1 kg/m
2 and
a t-score of -0.45 in the hip and -0.3 in the spine by
DEXA. Both groups were well matched in age, BMI and
b o n ed e n s i t y( T a b l e1 ) .T h e r ew e r em o r eW h i t ew o m e n
in the SW and more Asian women in PW groups.
Urinary silicon
The urinary creatinine was compatible between the
groups at baseline (82.2 ± 46.6 mg/dL in PW vs. 78.8 ±
43.2 mg/dL in SW groups) and there was not any signif-
icant change within groups during the study (p = 0.878).
The screening urinary silicon was 0.012 ± 0.008 mg/mg
creatinine in SW group and 0.012 ± 0.008 mg/mg crea-
tinine in PW group, obtained from a fasting single spot
collection. There was a decrease of silicon between
screen and baseline for the PW group but was not sta-
tistically significant. The urinary silicon level increased
significantly from 0.016 ± 0.010 mg/mg creatinine at
baseline to 0.037 ± 0.014 mg/mg creatinine at week 12
in the SW group (p = 0.003), but there was no change
for the PW group (0.010 ± 0.004 mg/mg creatinine at
baseline vs. 0.009 ± 0.006 mg/mg creatinine at week 12,
p = 0.679). At the end of the study, the urinary silicon
for the SW group increased by 133.5% which was a sta-
tistically significant increase by comparison to the PW
group (p < 0.01) (Figure 1).
Urinary N-telopeptide
Urinary collagen type 1 cross-linked N-telopeptide
excretion was normalized to creatinine in a fasting spot
urine sample as a reflection of daily NTx. There was not
any significant difference for baseline NTx levels
between the two groups (36.0 ± 18.0 nmol/mmol in SW
vs. 27.2 ± 11.5 nmol/mmol creatinine in PW). At the
end of the study, differences between the groups were
insignificant (36.0 ± 17.4 nmol/mmol in SW vs. 27.4 ±








Age (years) 53.1 ± 6.5 54.4 ± 3.9
BMI (kg/m
2) 23.4 ± 3.3 24.8 ± 4.5






T-score Total Hip -0.6 ± 1.1 -0.5 ± 1.5
Lumbar Spine -0.4 ± 1.6 -0.2 ± 1.2
BMD (g/cm
2) Total Hip 0.9 ± 0.1 1.0 ± 0.3
Lumbar Spine 1.2 ± 0.2 1.2 ± 0.3
Values are listed as mean ± SD.
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statistic difference within groups either.
Serum bone turnover markers
All the subjects had normal calcium levels during the
entire study. One subject in the PW group had low vita-
min D 25-hydroxy level (15 ng/ml) in spite of vitamin D
supplementation. Baseline bone metabolism marker
levels were not significantly different between groups.
There as a wide variation in bone marker level in both
groups at baseline and week 12. There was no change of
parathyroid hormone or markers of bone formation
including procollagen type I intact, N-terminal propep-
tide, bone specific alkaline phosphatase, and osteocalcin
within groups or between groups (Table 2).
Discussion
Since the silicon deprivation studies [15,16] that sug-
gested a potential role of silicon in bone and connective
tissue health, there have been many studies investigating
the potential role of dietary silicon in bone health [21].
Schiano et al reported that supplementation with soluble
salt of silicium resulted in a significant increase in the
total bone volume both in drinkable and in injectable
form [22]. In a later study, silicon was shown to be
more effective than Etidronate and sodium fluoride over
a 14 to 22 month period [23]. In a recent double blind,
placebo-controlled 12 month trial in osteopenic and
osteoporotic subjects, Spector et al [24] reported that
oral choline-stabilized orthosilicic acid had potential
beneficial effects on bone collagen and a trend for a
dose-related decrease in the bone resorption marker,
collagen type 1 C-terminal telopeptide at 6 and 12
months.
The primary aim of the present study was to investi-
gate the absorption of bottled silicon water. As much as
50% of ingested silicon is excreted in the urine [25].
Urinary excretion of silicon is a good marker of
absorbed silicon and correlates well with dietary intake
of silicon [19]. We clearly demonstrated that 86 mg/day
of silica provided with bottled water significantly
increased the urinary excretion of silicon.
The main route of entry of silicon to the body is from
the gastrointestinal tract. Gastrointestinal uptake of sili-
con from foods was estimated in women as 24 mg/day
and men as 30 mg per day. The major food sources are
beer and bananas in men, and bananas and string beans
in women [26]. It should be noted, however, that higher
intakes of alcohol are associated with reduced bone den-
sity. Foods can be a major source of silicon [27,28], but
in our study the intake of silicon-rich water from an
artesian aquifer significantly increased silicon excretion
over what was being excreted from dietary sources.
Asians and Indians have much higher silicon intakes
than do Western populations [29,30], and also have a
lower incidence of hip fracture [31]. In addition, silicon
intake decreases with age, with an average 0.1 mg less
for every additional year of age [26]. Bottled silicon-rich
water can be an additional source to improve silicon
intake.
The present study did not demonstrate any significant
change of bone metabolism markers in 12 weeks. All
the study subjects were postmenopausal women. In the
Framingham offspring cohort study Jugdaohsingh et al
found that silicon intake was positively associated with
bone mineral density for men and premenopausal
Figure 1 Urine silicon.M e a n±S D .F a s t i n gs p o tu r i n ew a s
collected for urine creatinine and silicon. *silicon increased
significantly (p < 0.05) in the silicon-rich water group from baseline
to Week 12. No change was seen for the purified water group.
Table 2 Serum bone turnover markers
Silicon-rich Water Purified Water
Screen Baseline Week 12 Screen Baseline Week 12
Calcium (mg/L) 94.3 ± 1.4 93.7 ± 3.4 92.6 ± 3.4 94.7 ± 3.5 94.0 ± 3.9 93.3 ± 3.4
Bone specific Alk Phos (mcg/L) 13.9 ± 4.3 13.4 ± 4.1 13.0 ± 3.4 13.6 ± 13.4 14.5 ± 3.0 13.3 ± 3.4
Osteocalcin (ng/mL) 21.4 ± 8.0 18.0 ± 6.7 20.3 ± 6.8 20.7 ± 6.3 15.1 ± 4.0 17.7 ± 5.0
Procollagen t1 propeptide (μg/L) 62.3 ± 31.4 62.6 ± 28.3 55.8 ± 21.8 46.7 ± 22.1 57.6 ± 14.7 56.0 ± 19.1
PTH intact (pg/mL) 39.0 ± 9.6 33.3 ± 10.9 37.4 ± 12.2 38.4 ± 12.4 37.3 ± 15.4 44.1 ± 21.6
Vitamin D, 25 hydroxy (ng/mL) 29.2 ± 12.6 27.8 ± 10.4 27.0 ± 8.1 23.1 ± 8.2 23.5 ± 7.1 27.9 ± 11.1
Values are listed as mean ± SD.
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or premenopausal women may respond to silicon rich
water differently. In the osteoporosis drug treatment
studies the bone metabolism markers are mostly mea-
sured no earlier than 6 month [32-34]. This study was
only 12 weeks. A longer supplementation period or
lower BMD group may therefore have shown a greater
effect of Si. It has been previously suggested that the
effect of silicon is best under low calcium intake. Indeed
a recent study by Kim et al [35] reported that Si supple-
mentation increased bone mineral density in ovariecto-
mised rats, only when the feed was deficient in calcium.
No effect was seen under calcium replete or high cal-
cium intake group. Finally change of short-term markers
of bone resorption may not be the only mechanisms by
which silicon improves bone health.
There have been conflicting reports on the influence
of calcium and vitamin D on bone metabolic markers
demonstrating no effect on markers of bone turnover
but effects on bone loss [36,37]. To eliminate the poten-
tial effects of vitamin D and calcium deficiency on bone
markers, all subjects in the present study were supple-
mented with vitamin D and calcium. We did not see
any additional benefit of silicon supplementation on
short-term markers of bone remodeling over 12 weeks.
Further research including studies over several years
examining changes in bone density following long-term
daily consumption of silicon-rich water obtained from
artesian aquifers in women with reduced bone density
are needed.
Conclusions
This study clearly demonstrated that 86 mg/day of silica
from bottled water increased urinary excretion of silicon
over a 12-week period in post-menopausal women. This
indicates that artesian aquifer bottled water is a safe and
effective way of providing easily absorbed dietary silicon
to the body. Although the silicon did not affect bone
turnover in the short-term, the mineral’s potential as an
alternative prevention or treatment to drug therapy for
osteoporosis warrants further, longer-term investigation
in the future.
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